...
首页> 外文期刊>Scientific reports. >Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis
【24h】

Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis

机译:与侵袭性导管癌相比,乳腺癌患者的侵袭性微小癌患者没有差异:匹配匹配分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Invasive micropapillary carcinoma (IMPC) is a rare histopathological variant of breast carcinoma that is usually associated with poor clinical characteristics. Whether IMPC has worse prognosis than invasive ductal carcinoma (IDC) is controversial. This retrospective study examined the prognostic difference between IMPC and IDC. We analysed 327 cases of IMPC patients and 4979 IDC cases who underwent primary resection in our institution between 2008 and 2012. Using propensity score matching, the two groups were matched at 1:1 by age, tumour size, nodal status, hormone status, and HER2 status. Differences in prognosis were assessed by Kaplan-Meier estimates and Cox regression analysis. We established the IMPC group and identified 324 IDC patients by propensity score matching. The survival analysis indicated that IMPC patients had no significant reduced overall survival (p?=?0.752) or disease-free survival (p?=?0.578) compared with IDC patients. Multivariate Cox regression analysis revealed that IMPC was not an independent prognostic factor for disease-free survival (hazard ratio [HR]?=?0.944; 95% confidential interval [CI], 0.601-1.481) or overall survival (HR?=?0.727; 95% CI, 0.358-1.478). Survival analysis demonstrated no statistically significant difference between IMPC and IDC, indicating that proactive or radical clinical therapy is unnecessary.
机译:侵袭性微癌癌(IMPC)是乳腺癌的罕见组织病理学变体,通常与临床特征差。 IMPC是否具有比侵入性导管癌(IDC)更差的预后是有争议的。该回顾性研究检测了IMPC和IDC之间的预后差异。我们分析了327例IMPC患者患者和4979例IDC病例,在2008年和2012年期间接受了初级切除的IDC病例。使用倾向得分匹配,两组逐年,肿瘤规模,节点状况,激素状况与1:1匹配HER2状态。 Kaplan-Meier估计和COX回归分析评估预后的差异。我们通过倾向得分匹配建立了IMPC组并确定了324名IDC患者。生存分析表明,与IDC患者相比,IMPC患者没有显着降低的整体存活率(P?= 0.752)或无疾病存活(P?= 0.578)。多元COX回归分析显示,IMPC不是无疾病存活的独立预后因素(危害比[HR] = 0.944; 95%机密间隔[CI],0.601-1.481)或总体存活(HR?= 0.727 ; 95%CI,0.358-1.478)。存活分析证明了IMPC和IDC之间没有统计学上有显着差异,表明不需要积极或激进的临床疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号